Naleway 2023 compared antibody responses to high-dose egg-based inactivated (HD-IIV3), recombinant (RIV4), and cell culture–based (ccIIV4) vs standard-dose egg-based inactivated (SD-IIV4) influenza vaccine among health care personnel aged 18 to 65 years in 2 influenza seasons. They found that HD-IIV3 did not induce higher antibody responses than SD-IIV4, but, consistent with previous studies, RIV4 was associated with higher post-vaccination antibody titers.
Milestone
3.2.d
Antigen dose adjustment
In progress
Determine the utility of further adjusting antigen doses in existing seasonal influenza vaccines for different populations and age-groups.
Progress Highlights
Pahmeier 2023 used an age-stratified deterministic compartment model to calculate the impact of vaccinating the German population aged 60 years and over for the 2019-2020 season with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs. simulate the course of influenza infection for the 2019-2020 season. They found that achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and older would result in lower costs and fewer influenza infections compared with the scenario with IIV4-HD and actual vaccination rates.